<DOC>
	<DOCNO>NCT00705367</DOCNO>
	<brief_summary>The purpose study determine whether abatacept dose 30 mg/kg via intravenous infusion safe well tolerate treatment lupus nephritis mainland Chinese subject systemic lupus erythematosus ( SLE )</brief_summary>
	<brief_title>Phase I Study China - Tolerability Single Dose Abatacept 30 mg/kg</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Men woman , least 18 year age , diagnosis systemic lupus erythematosus ( SLE ) lupus nephritis currently stable last 3 month without change treatment lupus nephritis Stable renal disease No flaring organ system minimum last 3 month Unstable lupus nephritis serum creatinine &gt; 3 mg/dL Progressive renal failure , end stage renal disease , renal transplant require continuous dialysis Severe unstable , refractory , progressive SLE History cancer Participants risk tuberculosis Autoimmune disease SLE main diagnosis Human immunodeficiency virus herpes zoster infection HepatitisB surface antigenpositive hepatitis C antibodypositive participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>